Benzinga | Nov 24, 2020 08:10AM EST

Morgan Stanley Initiates Coverage On Atea Pharmaceuticals with Overweight Rating, Announces Price Target of $49

Morgan Stanley initiates coverage on Atea Pharmaceuticals (NASDAQ:AVIR) with a Overweight rating and announces Price Target of $49.